Wanle Pharmaceutical

Shenzhen Wanle Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company specializing in the research, development, and manufacturing of oncology medications. Established in 1990 and headquartered in Shenzhen, the company has grown into a major producer of antineoplastic agents, including cytotoxic drugs and supportive care therapies. Wanle operates multiple GMP-certified production lines and is particularly noted for its expertise in freeze-dried powder injections and small-volume liquid injections. Currently operating as a subsidiary of China Resources Pharmaceutical Group (CR Pharma), the company maintains a dominant position in the domestic oncology market while also producing cardiovascular and anti-infective treatments. Their portfolio includes high-quality generic versions of essential chemotherapy drugs such as doxorubicin, paclitaxel, and epirubicin.